Recent Company News

• 08:07 AM ET Sep 16, 2025
  

  FDA grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 targeting ADC CRB-701 in head and neck squamous cell carcinoma ($9.37, 0.00)

• 06:36 AM ET Sep 15, 2025
  

  NMPA approves CSPC Pharmaceutical Group's ALMB-0166 to phase II clinical trial for treatment of Parkinson's disease (HK$10.54, 0.00)

• 06:45 AM ET Sep 12, 2025
  

  CSPC Pharmaceutical Group obtains NMPA clinical trial approval for SYH2066 Tablets (HK$10.35, 0.00)

• 07:46 AM ET Sep 11, 2025
  

  CSPC Pharmaceutical Group's new drug application for KN026 (Anbenitamab Injection) accepted by NMPA (HK$10.12, 0.00)

• 12:02 AM ET Sep 11, 2025
  

  StreetAccount Summary - Trading higher/lower: Asia mid-morning

• 11:13 PM ET Sep 10, 2025
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 09:08 AM ET Sep 10, 2025
  

  Trump administration weighing restrictions on drugs from China -- NY Times

• 03:46 AM ET Sep 09, 2025
  

  StreetAccount Summary: Hong Kong Stocks reaching new 52-week highs/lows (35 total)

• 12:15 AM ET Sep 09, 2025
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (159 total)

• 03:36 AM ET Sep 04, 2025
  

  StreetAccount Summary: Hong Kong Stocks reaching new 52-week highs/lows (20 total)